{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:53:06Z","timestamp":1790124786097,"version":"4.0.1"},"reference-count":259,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":5759,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:p>Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem. Obesity is caused by an imbalance between caloric intake and energy expenditure, which is influenced by both environmental and genetic factors. Pharmacologic treatments include anorexigenic agents, which fall into two broad categories: those that act via brain catecholamine pathways and those that act via serotonin pathways. The most recent oral agents approved are dexfenfluramine, which is currently being marketed, and sibutramine. Both agents inhibit the control reuptake of serotonin but in addition may have effects on thermogenesis. Under investigation are agents that increase energy expenditure: the \u03b2<jats:sub>3<\/jats:sub>\u2010adrenergic receptor agonists and drugs that prevent the intestinal absorption of free fatty acids and cholesterol. In development are innovative approaches to influence leptin and its receptors, various obesity genes, and biologic substances thought to influence satiety (neuropeptide Y, enterostatin, cholecystokinin, bombesin, and amylin). Obesity has now become a major target for drug development not only for affecting obesity per se but also for managing and preventing comorbid conditions such as diabetes and cardiovascular disease.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1997.tb04323.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T18:43:09Z","timestamp":1362768189000},"page":"453-473","source":"Crossref","is-referenced-by-count":47,"title":["The Pharmacologic Approach to the Treatment of Obesity"],"prefix":"10.1002","volume":"37","author":[{"given":"Mitchell","family":"Weiser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dror","family":"Michaelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Anwar","family":"Abdeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510180077038"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/jama.1994.03520030047027","article-title":"Increasing prevalence of overweight among U.S. adults: the National Health and Nutrition Examination Surveys 1960 to 1991","volume":"272","author":"Kuczmarski RJ","year":"1994","journal-title":"JAMA"},{"key":"e_1_2_1_4_2","first-page":"465","volume-title":"Obesity.","author":"Anderson KM","year":"1992"},{"key":"e_1_2_1_5_2","first-page":"1","article-title":"1983 Metropolitan Height and Weight Tables Statistical Bulletin","volume":"64","year":"1983","journal-title":"Metropolitan Life Insurance Company"},{"key":"e_1_2_1_6_2","volume-title":"Plan and Operation of the National Health and Nutrition Examination Survey, 1976\u201380.","author":"National Center for Health Statistics","year":"1981"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-6-983"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00006"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1978.03290150053024"},{"issue":"321","key":"e_1_2_1_10_2","first-page":"1","article-title":"The blood pressure in a population: blood pressure readings and height and weight determinations in the adult population of the city of Bergen","volume":"157","author":"Boe J","year":"1957","journal-title":"Acta Med Scand"},{"key":"e_1_2_1_11_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/oxfordjournals.aje.a120517","article-title":"Prevalence of chronic diseases and distribution of selected physiologic variables in a total community, Tecumsch, Michigan","volume":"81","author":"Epstein FH","year":"1965","journal-title":"Am J Epidemiol"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198402000-00015"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/1.4.335"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198708000-00002"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107996"},{"key":"e_1_2_1_16_2","first-page":"S254","article-title":"Mechanisms of hypertension in obesity","volume":"22","author":"Dornfeld LP","year":"1987","journal-title":"Kidney Int Suppl"},{"key":"e_1_2_1_17_2","first-page":"IV\u201062","article-title":"Plasma high\u2010density lipoprotein cholesterol: association with measurements of body mass. The Lipid Research Clinical Program Prevalence Study","volume":"62","author":"Glueck CJ","year":"1980","journal-title":"Circulation"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/ajcn\/18.6.397","article-title":"Relationship between serum cholesterol and body fatness: an epidemiologic study","volume":"18","author":"Montoye JE","year":"1966","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_19_2","first-page":"502","volume-title":"Obesity.","author":"Assman G","year":"1992"},{"key":"e_1_2_1_20_2","first-page":"125","volume-title":"Obesity in America.","author":"Kannel WB","year":"1979"},{"key":"e_1_2_1_21_2","first-page":"143","volume-title":"Medical Complications of Obesity.","author":"Farinaro E","year":"1979"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196203082661003"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113079"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-7-199504010-00001"},{"key":"e_1_2_1_25_2","volume-title":"Report of the National Commission on Diabetes to the Congress of the United States","author":"United States National Commission on Diabetes","year":"1975"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/21.12.1434"},{"key":"e_1_2_1_27_2","first-page":"67A","article-title":"Abnormal fat distribution in subjects predisposed to NIDDM (abstract)","volume":"33","author":"Ward WK","year":"1985","journal-title":"Clin Res"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.25.12.1154"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199003293221303"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410170095042"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91605-9"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.289.6454.1257"},{"key":"e_1_2_1_33_2","first-page":"79","article-title":"The epidemiology of gallstones","volume":"14","author":"Burnett W","year":"1971","journal-title":"Tijdschr Gastroenterol"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0272-5231(21)00055-1","article-title":"The cardiorespiratory effects of obesity","volume":"1","author":"Sharp JT","year":"1980","journal-title":"Clin Chest Med"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.35.4.349"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.77.3.317"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-6-1043"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/32.12.2723"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.1993.03510230061036","article-title":"Body weight and mortality: a 27 year follow\u2010up of middle\u2010aged men","volume":"270","author":"Lee IM","year":"1993","journal-title":"JAMA"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199509143331101"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/45.5.1120"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89464-8"},{"key":"e_1_2_1_43_2","first-page":"13","volume-title":"Obesity: Theory and Therapy.","author":"Sjostrom L","year":"1992"},{"key":"e_1_2_1_44_2","first-page":"14","article-title":"Vash PD: Obesity","author":"Stark RET","year":"1992","journal-title":"The Bariatrician"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-6-1073"},{"key":"e_1_2_1_46_2","first-page":"397","article-title":"Beneficial effects of moderate weight loss","volume":"16","author":"Goldstein DJ","year":"1992","journal-title":"Int J Obes"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001504-199312000-00015"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.105.2.260"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/52.3.421"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112054"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1249\/00005768-199206001-00003"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1079\/BJN19610003"},{"key":"e_1_2_1_53_2","doi-asserted-by":"crossref","first-page":"242S","DOI":"10.1093\/ajcn\/55.1.242s","article-title":"A brief overview of human energy, metabolism and its relationship to essential obesity","volume":"55","author":"Ravussin E","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_54_2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/ajcn\/20.11.1212","article-title":"Gluttony: parts I and II","volume":"20","author":"Miller DS","year":"1967","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_55_2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/ajcn\/21.12.1455","article-title":"Endocrine and metabolic adaptation to obesity and starvation","volume":"21","author":"Simms EAH","year":"1968","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_56_2","volume-title":"Energy Balance and Obesity in Man.","author":"Garrow JS","year":"1978"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-097X.1983.tb00692.x"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/372425a0"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340511"},{"key":"e_1_2_1_60_2","first-page":"38","article-title":"Mouse models of human obesity","volume":"4137","author":"Weigle DS","year":"1997","journal-title":"Sci Med"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340503"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/379632a0"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508103330605"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1965.tb34807.x"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005243222102"},{"key":"e_1_2_1_66_2","first-page":"81","article-title":"Problems in the genetics of human obesity","volume":"56","author":"Withers RFJ","year":"1964","journal-title":"Eugenics Rev"},{"key":"e_1_2_1_67_2","volume-title":"Pharmacological Treatment of Obesity.","author":"Brodoff BN","year":"1995"},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM193801202180307"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1937.02780070012004"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1021\/ie50422a005"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243060-00003"},{"key":"e_1_2_1_72_2","doi-asserted-by":"crossref","first-page":"193S","DOI":"10.1093\/ajcn\/55.1.193s","article-title":"Overview of adrenergic anorectic agents","volume":"55","author":"Wellman PJ","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_73_2","first-page":"132","volume-title":"Phenylpropanolamine: A Review.","author":"Lasagna L","year":"1988"},{"key":"e_1_2_1_74_2","first-page":"211","article-title":"Double\u2010blind clinical evaluation of the anorectic activity of phenylpropanolamine hydrochloride drops and placebo drops in the treatment of exogenous obesity","volume":"40","author":"Altschuler S","year":"1986","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_75_2","first-page":"584","article-title":"A double\u2010blind clinical evaluation of the anorectic activity of phenylpropanolamine versus placebo","volume":"11","author":"Greenway F","year":"1989","journal-title":"Clin Ther"},{"issue":"2","key":"e_1_2_1_76_2","first-page":"48","article-title":"Effectiveness of phenylpropanolamine as an adjunct in the dietary management of obesity (abstract)","volume":"14","author":"Schteingart D","year":"1990","journal-title":"Int J Obesity"},{"key":"e_1_2_1_77_2","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/ajcn\/55.1.203s","article-title":"Clinical studies with phenylpropanolamine: a meta analysis","volume":"55","author":"Greenway FL","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_78_2","first-page":"79","article-title":"Phenylpropanolamine: toward resolution of a controversy editorial","volume":"11","author":"Winick C","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198902000-00007"},{"key":"e_1_2_1_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420220081031"},{"key":"e_1_2_1_81_2","first-page":"74","article-title":"The effects of phenylpropanolamine hydrochloride in overweight patients with controlled stable hypertension","volume":"46","author":"Bradley MH","year":"1989","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_82_2","first-page":"2439","volume-title":"AMA Drug Evaluations Annual.","year":"1995"},{"key":"e_1_2_1_83_2","unstructured":"Advance notice of proposed role (ANPR) making for OTC weight control drug products(17\u2010FR\u20108466 8471 8477)Feb 1982."},{"key":"e_1_2_1_84_2","unstructured":"Letter from FDA to Non\u2010prescription Drug Manufacturers Association.March 9 1993."},{"issue":"2","key":"e_1_2_1_85_2","first-page":"138","article-title":"Double\u2010blind trial comparing fenfluramine, phentermine and dietary advice on treatment of obesity","volume":"14","author":"Tuominen S","year":"1980","journal-title":"Int J Obes"},{"key":"e_1_2_1_86_2","first-page":"851","article-title":"A controlled trial of phentermine in obese patients","volume":"218","author":"Campbell C","year":"1977","journal-title":"Practitioner"},{"issue":"6","key":"e_1_2_1_87_2","first-page":"591","article-title":"Plasma phentermine levels, weight loss and side effects","volume":"7","author":"Douglas A","year":"1983","journal-title":"Int J Obesity"},{"key":"e_1_2_1_88_2","first-page":"391","volume-title":"Central Mechanisms of Anorectic Drugs.","author":"Hoekenga MT","year":"1978"},{"key":"e_1_2_1_89_2","first-page":"678","article-title":"A double blind trial of diethylpropion hydrochloride, mazindol and placebo in the treatment of erogenous obesity","volume":"22","author":"Allen GS","year":"1977","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_90_2","first-page":"40","article-title":"Diethylpropion hydrochloride: an effective appetite suppressant","volume":"16","author":"Bolding OT","year":"1974","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_91_2","first-page":"167","article-title":"Pharmacological treatment of obesity","volume":"2","author":"Sullivan AC","year":"1979","journal-title":"Int J Obes"},{"key":"e_1_2_1_92_2","first-page":"461","volume-title":"Central Mechanisms of Anorectic Drugs.","author":"Carabillo EA","year":"1978"},{"key":"e_1_2_1_93_2","first-page":"23","volume-title":"Drugs and Appetite.","author":"Samanin R","year":"1982"},{"key":"e_1_2_1_94_2","first-page":"93","volume-title":"Drugs and Appetite.","author":"Silverstone T","year":"1982"},{"issue":"2","key":"e_1_2_1_95_2","first-page":"34","article-title":"Clinical evaluation of mazindol, an anorexiant on obesity","volume":"14","author":"Onishi T","year":"1990","journal-title":"Int J Obes"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-015-1132-2_4"},{"key":"e_1_2_1_97_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/030006057400200505","article-title":"Mazindol in obesity with known cardiac disease","volume":"2","author":"Bradley MJ","year":"1974","journal-title":"J Int Med Res"},{"key":"e_1_2_1_98_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0022-3565(25)39173-1","article-title":"Reinforcing and subjective effects of several anorectics on normal human volunteers","volume":"242","author":"Chait LD","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_99_2","unstructured":"WurtmanR WurtmanJ:Serotonin and eating disorders (abstract). Presented at the Satellite Symposium at the 70th International Congress on Obesity on Pharmacologic Treatment of Obesity. Saint\u2010Adede Quebec August 1820 1994;6."},{"key":"e_1_2_1_100_2","first-page":"751","volume-title":"Obesity.","author":"Nathan C","year":"1992"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6663(88)80004-7"},{"key":"e_1_2_1_102_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199010000-00001"},{"key":"e_1_2_1_103_2","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcn\/60.5.647","article-title":"Long\u2010term weight loss: the effect of pharmacologic agents","volume":"60","author":"Goldstein DJ","year":"1994","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00406875"},{"key":"e_1_2_1_105_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007997909117496"},{"key":"e_1_2_1_106_2","first-page":"465","article-title":"Plasma concentration of fenfluramine and its metabolite, norfenfluramine following single and repeated oral administration","volume":"43","author":"Campbell DB","year":"1971","journal-title":"Br J Pharmacol"},{"issue":"1","key":"e_1_2_1_107_2","first-page":"171","article-title":"The anorectic activity of fenfluramine","volume":"51","author":"Silverstone JT","year":"1975","journal-title":"Postgrad Med J"},{"key":"e_1_2_1_108_2","first-page":"125","volume-title":"Drugs and Appetite.","author":"Munro JF","year":"1982"},{"key":"e_1_2_1_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.84"},{"key":"e_1_2_1_110_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-7_Part_2-199310011-00016"},{"key":"e_1_2_1_111_2","first-page":"74","article-title":"Fenfluramine: study of its central action through its effects on sleep","volume":"1","author":"Gagnon M","year":"1969","journal-title":"Int J Clin Pharmacol"},{"key":"e_1_2_1_112_2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite suppresant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim L","year":"1996","journal-title":"N Engl J Med"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.70.6.537"},{"key":"e_1_2_1_114_2","first-page":"58","article-title":"Prescription pharmaceuticals and biotechnology","author":"FDC Reports","year":"1996","journal-title":"The Pink Sheet"},{"key":"e_1_2_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(95)90207-4"},{"issue":"1","key":"e_1_2_1_116_2","first-page":"528","article-title":"Progress in assessing the role of serotonin in the control of food intake","volume":"11","author":"Garattini S","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6663(86)80050-2"},{"key":"e_1_2_1_118_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243060-00003"},{"key":"e_1_2_1_119_2","volume-title":"Dexfenfluramine: prescribing information","year":"1996"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1038\/380488a0"},{"issue":"1","key":"e_1_2_1_121_2","first-page":"S51","article-title":"Hypothalmic serotonin: pharmacological, biochemical and behavioral analyses of its feeding\u2010suppressive action","volume":"11","author":"Leibowitz SF","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315204"},{"key":"e_1_2_1_123_2","first-page":"180","article-title":"Dexfenfluramine treatment of obesity: a double\u2010blind trial with post trial follow up","volume":"19","author":"O'Connor HT","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.14.4.325"},{"key":"e_1_2_1_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90366-X"},{"key":"e_1_2_1_126_2","unstructured":"GoodallE CorneyR StantonR BrownePB:Changes in food preference in premenstrual syndrome. Presented at the First European Congress on Obesity Stockholm 1988."},{"key":"e_1_2_1_127_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-108X(198711)6:6<687::AID-EAT2260060602>3.0.CO;2-O"},{"issue":"1","key":"e_1_2_1_128_2","first-page":"79","article-title":"D\u2010fenfluramine selectively decreases carbohydrate but not protein intake in obese subjects","volume":"8","author":"Wurtman JJ","year":"1984","journal-title":"Int J Obes"},{"key":"e_1_2_1_129_2","first-page":"445","volume-title":"Diabetes Mellitus and Obesity.","author":"Bernstein JG","year":"1982"},{"key":"e_1_2_1_130_2","first-page":"659","article-title":"Focus on dexfenfluramine: a serotonin reuptake inhibitor for the management of obesity","volume":"31","author":"Owens CA","year":"1996","journal-title":"Formulary"},{"issue":"1","key":"e_1_2_1_131_2","first-page":"S90","article-title":"Enhancement of the thermic effect of food by d\u2010fenfluramine","volume":"11","author":"Levitsky DA","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_132_2","first-page":"613","article-title":"The effect of long\u2010term dexfenfluramine treatment on 24\u2010hour energy expenditure in man: a double blind placebo controlled study","volume":"14","author":"Breum L","year":"1990","journal-title":"Int J Obes"},{"issue":"979","key":"e_1_2_1_133_2","first-page":"64","article-title":"Dexfenfluramine for obesity","volume":"38","year":"1996","journal-title":"Med Lett"},{"key":"e_1_2_1_134_2","first-page":"847","article-title":"Dexfenfluramine in the treatment of refractory obesity","volume":"38","author":"Finer N","year":"1985","journal-title":"Curr Ther Res"},{"issue":"1","key":"e_1_2_1_135_2","first-page":"S179","article-title":"Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom","volume":"11","author":"Finer N","year":"1988","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"e_1_2_1_136_2","first-page":"S173","article-title":"Efficacy and safety of dexfenfluramine in obese patients: a multicenter study","author":"Enzi G","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_137_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199512000-00010"},{"issue":"2","key":"e_1_2_1_138_2","first-page":"91","article-title":"Prolonged use of a very low calorie diet (Cambridge Diet) in massively obese patients attending an obesity clinic: safety, efficacy and additional benefit from dexfenfluramine","volume":"13","author":"Finer N","year":"1989","journal-title":"Int J Obes"},{"key":"e_1_2_1_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91499-2"},{"key":"e_1_2_1_140_2","first-page":"612","article-title":"A six\u2010month study of the effects of dexfenfluramine on partially successful dieters","volume":"47","author":"Noble RE","year":"1990","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_141_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00560.x"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199000393-00007"},{"key":"e_1_2_1_143_2","first-page":"552","article-title":"FDA news and product notes","volume":"31","year":"1996","journal-title":"Formulary"},{"key":"e_1_2_1_144_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243050-00007"},{"key":"e_1_2_1_145_2","first-page":"650","article-title":"Major depression during dexfenfluramine treatment (letter)","volume":"18","author":"Toornvliet AC","year":"1994","journal-title":"Int J Obes"},{"key":"e_1_2_1_146_2","volume-title":"Dexfenfluramine: Formulary service information form","year":"1996"},{"issue":"936","key":"e_1_2_1_147_2","first-page":"107","article-title":"Fluoxetine (Prozac) and other drugs for treatment of obesity","volume":"36","year":"1994","journal-title":"Med Lett"},{"key":"e_1_2_1_148_2","first-page":"361","article-title":"The effects of 5\u2010HT reuptake inhibitor fluoxetine on food intake and body weight in healthy male subjects","volume":"14","author":"McGuirk J","year":"1990","journal-title":"Int J Obes"},{"issue":"2","key":"e_1_2_1_149_2","first-page":"141","article-title":"Effects of fluxetine on appetite, food intake and body weight in obese subjects","volume":"14","author":"McGuirk J","year":"1990","journal-title":"Int J Obes"},{"key":"e_1_2_1_150_2","first-page":"635","article-title":"Use of fluoxetine in the treatment of obesity","volume":"13","author":"Levine LR","year":"1989","journal-title":"Int J Obes"},{"issue":"3","key":"e_1_2_1_151_2","first-page":"163","article-title":"Fluxetine induced weight loss in overweight non depressed subjects","volume":"11","author":"Ferguson JM","year":"1987","journal-title":"Int J Obes"},{"issue":"2","key":"e_1_2_1_152_2","first-page":"154","article-title":"Fluoxetine has potential in obese NIDDM\u2010Multicenter Canadian trial (abstract)","volume":"38","author":"Chiasson JL","year":"1989","journal-title":"Diabetes"},{"key":"e_1_2_1_153_2","doi-asserted-by":"publisher","DOI":"10.1159\/000177857"},{"key":"e_1_2_1_154_2","first-page":"129","article-title":"Fluoxetine: a randomized clinical trial in the treatment of obesity","volume":"18","author":"Goldstein DJ","year":"1994","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_1_155_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.147.7.876"},{"issue":"2","key":"e_1_2_1_156_2","first-page":"48","article-title":"Eight weeks fluoxetine therapy in obese patients with impaired glucose tolerance","volume":"14","author":"Kutnowski M","year":"1990","journal-title":"Int J Obes"},{"key":"e_1_2_1_157_2","first-page":"232","article-title":"A comparative trial of different regimens of fenfluramine and phentermine in obesity","volume":"211","author":"Steel JM","year":"1973","journal-title":"Practitioner"},{"key":"e_1_2_1_158_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.69"},{"issue":"1","key":"e_1_2_1_159_2","first-page":"241","article-title":"Pharmacological modulation of lipid metabolism for the treatment of obesity","volume":"8","author":"Sullivan AC","year":"1984","journal-title":"Int J Obes"},{"key":"e_1_2_1_160_2","doi-asserted-by":"publisher","DOI":"10.1038\/309163a0"},{"key":"e_1_2_1_161_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90007-4"},{"key":"e_1_2_1_162_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2570461"},{"key":"e_1_2_1_163_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1991.tb04940.x"},{"key":"e_1_2_1_164_2","first-page":"895","article-title":"Molecular cloning and expression of the rat \u03b23\u2010adrenergic receptor","volume":"40","author":"Granneman JG","year":"1991","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_165_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1320377"},{"key":"e_1_2_1_166_2","volume-title":"Beta3\u2010Adrenergic Agonism: A New Concept in Human Pharmacotherapy.","author":"Goldberg DE","year":"1995"},{"key":"e_1_2_1_167_2","first-page":"299","volume-title":"Brown Adipose Tissue.","author":"Trayhurn P","year":"1986"},{"key":"e_1_2_1_168_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7827(89)90009-X"},{"key":"e_1_2_1_169_2","doi-asserted-by":"publisher","DOI":"10.1038\/366740a0"},{"key":"e_1_2_1_170_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00174.x"},{"key":"e_1_2_1_171_2","doi-asserted-by":"publisher","DOI":"10.1016\/0020-711X(91)90062-R"},{"key":"e_1_2_1_172_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116191"},{"key":"e_1_2_1_173_2","first-page":"678","article-title":"Contribution of the beta 3\u2010adrenoceptor activation to ephedrine\u2010induced thermogenesis in humans","volume":"19","author":"Liu YL","year":"1995","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_1_174_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508103330603"},{"key":"e_1_2_1_175_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199508103330604"},{"key":"e_1_2_1_176_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0022-3565(25)38092-4","article-title":"Desensitization of beta 1\u2010 and beta 2\u2010 but not beta 3\u2010adrenoceptor\u2010mediated lipolytic responses of adipocytes after long\u2010term epinephrine infusion","volume":"265","author":"Carpene C","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_177_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0026-895X(25)13419-6","article-title":"The human beta 3\u2010adrenergic receptor is resistant to short term agonist\u2010promoted desensitization","volume":"43","author":"Nantel F","year":"1993","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_178_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb13311.x"},{"key":"e_1_2_1_179_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4490"},{"key":"e_1_2_1_180_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1992.tb14251.x"},{"key":"e_1_2_1_181_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01928793"},{"key":"e_1_2_1_182_2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-3565(25)10443-6","article-title":"The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta\u20103 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms","volume":"263","author":"Tavernier G","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_183_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118823"},{"key":"e_1_2_1_184_2","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.1093\/ajcn\/55.1.258s","article-title":"Clinical studies with the \u03b2\u2010adrenoceptor agonist BRL 26830A","volume":"55","author":"Connacher AA","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_185_2","doi-asserted-by":"crossref","first-page":"252S","DOI":"10.1093\/ajcn\/55.1.252s","article-title":"BRL 35135, a potent and selective atypical \u03b2\u2010adrenoceptor agonist","volume":"55","author":"Cawthorne MA","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_186_2","doi-asserted-by":"crossref","first-page":"249S","DOI":"10.1093\/ajcn\/55.1.249s","article-title":"Thermogenic effects of various \u03b2\u2010adrenoceptor agonists in humans: their potential usefulness in the treatment of obesity","volume":"55","author":"Jequier E","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_187_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00094a025"},{"key":"e_1_2_1_188_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmr.5610040704"},{"key":"e_1_2_1_189_2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/ajcn\/33.2.506","article-title":"Two years of clinical experience with bilio\u2010pancreatic bypass for obesity","volume":"33","author":"Scopinaro N","year":"1980","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_190_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/bj2560357","article-title":"Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin","volume":"256","author":"Hadvary P","year":"1988","journal-title":"J Biochem"},{"key":"e_1_2_1_191_2","first-page":"241","article-title":"Lipase inhibition: a novel concept in the treatment of obesity","volume":"17","author":"Drent ML","year":"1993","journal-title":"Int J Obes"},{"key":"e_1_2_1_192_2","first-page":"221","article-title":"Orlistat (RO 18\u20130647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study","volume":"19","author":"Drent ML","year":"1995","journal-title":"Int J Obes"},{"key":"e_1_2_1_193_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00191901"},{"key":"e_1_2_1_194_2","first-page":"167","volume-title":"New Concepts in Depression.","author":"Buckett WR","year":"1987"},{"issue":"2","key":"e_1_2_1_195_2","first-page":"145","article-title":"Sibutramine: weight loss in depressed patients (abstract)","volume":"19","author":"Kelly F","year":"1995","journal-title":"Int J Obes"},{"key":"e_1_2_1_196_2","unstructured":"ConnoleyJP HealDJ:The thermogenic effects of sibutramine (abstract 52). Proceedings of Pharmacologic Treatment of Obesity Satellite Symposium of the Seventh International Congress on Obesity Saint Adele Quebec 1994."},{"key":"e_1_2_1_197_2","unstructured":"FantinoM MartelP:Decrease of food intake and weight loss induced by sibutramine in the rat (abstract 41). Proceedings of Pharmacologic Treatment of Obesity Satellite Symposium of the Seventh International Congress on Obesity Saint Adele Quebec 1994."},{"key":"e_1_2_1_198_2","unstructured":"KrongradStricker A BurletC:Sibutramine effects on feeding behavior: a dose dependence and micro structural analysis (abstract 53). Proceedings of Pharmacologic Treatment of Obesity Satellite Symposium of the Seventh International Congress on Obesity Saint Adele Quebec 1994."},{"key":"e_1_2_1_199_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1991.144"},{"key":"e_1_2_1_200_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1996.tb00544.x"},{"issue":"2","key":"e_1_2_1_201_2","first-page":"60","article-title":"A dose ranging study: efficacy and tolerability of sibutramine in weight loss (abstract)","volume":"18","author":"Drouin P","year":"1994","journal-title":"Int J Obes"},{"issue":"2","key":"e_1_2_1_202_2","first-page":"61","article-title":"Sibutramine hydrochloride: weight loss in overweight patients [abstract]","volume":"18","author":"Jones SP","year":"1994","journal-title":"Int J Obes"},{"key":"e_1_2_1_203_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1995.tb00227.x"},{"issue":"2","key":"e_1_2_1_204_2","first-page":"61","article-title":"Sibutramine hydrochloride vs. dexfenfluramine: weight loss in obese subjects (abstract)","volume":"18","author":"Kelly F","year":"1994","journal-title":"Int J Obes"},{"issue":"2","key":"e_1_2_1_205_2","first-page":"144","article-title":"Efficacy and tolerability of sibutramine versus dexfenfluramine in obese patients [abstract]","volume":"19","author":"Drouin P","year":"1995","journal-title":"Int J Obes"},{"key":"e_1_2_1_206_2","first-page":"188","article-title":"Effects of sibutramine vs. placebo in NIDDM (abstract)","volume":"54","author":"Vargas R","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"e_1_2_1_207_2","first-page":"41","article-title":"Sibutramine in the treatment of overweight non\u2010insulin dependent diabetics (abstract)","volume":"19","author":"Griffiths J","year":"1995","journal-title":"Int J Obes"},{"key":"e_1_2_1_208_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb05303.x"},{"issue":"5","key":"e_1_2_1_209_2","first-page":"213","article-title":"The effect of BTS 54 524, a novel antidepressant, on monamine reuptake and cardiovascular parameters in man (abstract)","author":"Wynne RD","year":"1986","journal-title":"Acta Pharmacol Toxicol"},{"issue":"2","key":"e_1_2_1_210_2","first-page":"144","article-title":"An evaluation of the cardiovascular effects of sibutramine in normal volunteers (abstract)","volume":"19","author":"Wynne RD","year":"1995","journal-title":"Int J Obes"},{"key":"e_1_2_1_211_2","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1950.0065"},{"key":"e_1_2_1_212_2","first-page":"517","article-title":"A neuroendocrine reappraisal of the dual\u2010centre hypothesis: its implications for obesity and insulin resistance","volume":"19","author":"Rohner\u2010Jeanrenaud F","year":"1995","journal-title":"Int J Obes"},{"key":"e_1_2_1_213_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.7.855"},{"key":"e_1_2_1_214_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0995-950"},{"key":"e_1_2_1_215_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0995-953"},{"key":"e_1_2_1_216_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340503"},{"key":"e_1_2_1_217_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90151-5"},{"key":"e_1_2_1_218_2","doi-asserted-by":"publisher","DOI":"10.1038\/377530a0"},{"key":"e_1_2_1_219_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199652030-00004"},{"key":"e_1_2_1_220_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(94)90076-0"},{"key":"e_1_2_1_221_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.33.040193.001521"},{"key":"e_1_2_1_222_2","first-page":"S41","article-title":"Neuropeptide Y and regulation of the cardiovascular system","volume":"12","author":"Shine J","year":"1994","journal-title":"J Hypertens"},{"key":"e_1_2_1_223_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199504000-00003"},{"key":"e_1_2_1_224_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(88)90109-7"},{"key":"e_1_2_1_225_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)90895-3"},{"key":"e_1_2_1_226_2","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(91)90350-W"},{"key":"e_1_2_1_227_2","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(91)90349-S"},{"key":"e_1_2_1_228_2","first-page":"701","article-title":"Enterostatin\u2014its ability to inhibit insulin secretion and to decrease high\u2010fat food intake","volume":"17","author":"Mei J","year":"1993","journal-title":"Int J Obes"},{"issue":"3","key":"e_1_2_1_229_2","first-page":"S51","article-title":"Pharmacological aspects of obesity treatment: towards the 21st century","volume":"19","author":"Blundell JE","year":"1995","journal-title":"Int J Obes"},{"key":"e_1_2_1_230_2","first-page":"59","volume-title":"Perspectives in Behavioral Medicine, Eating Regulation and Discontrol.","author":"Smith GP","year":"1988"},{"key":"e_1_2_1_231_2","first-page":"63","volume-title":"Obesity: Toward a Molecular Approach.","author":"Smith GP","year":"1990"},{"key":"e_1_2_1_232_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7268408"},{"key":"e_1_2_1_233_2","first-page":"R776","article-title":"Cholecystokinin persistently suppresses meal size but not food intake in free\u2010feeding rats","volume":"246","author":"West DB","year":"1984","journal-title":"Am J Physiol"},{"key":"e_1_2_1_234_2","first-page":"R676","article-title":"Food intake response to modulation of secretion of cholecystokinin in Zucker rats","volume":"244","author":"McLaughlin CL","year":"1983","journal-title":"Am J Physiol"},{"key":"e_1_2_1_235_2","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(78)90278-0"},{"key":"e_1_2_1_236_2","doi-asserted-by":"publisher","DOI":"10.1038\/302703a0"},{"key":"e_1_2_1_237_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/ajcn\/34.2.154","article-title":"C\u2010terminal octapeptide of cholecystokinin decreases food intake in man","volume":"34","author":"Kissilef HR","year":"1981","journal-title":"Am J Clin Nutr"},{"key":"e_1_2_1_238_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-0115(93)90410-A"},{"key":"e_1_2_1_239_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90397-2"},{"key":"e_1_2_1_240_2","doi-asserted-by":"publisher","DOI":"10.1038\/380403a0"},{"key":"e_1_2_1_241_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(85)90458-9"},{"key":"e_1_2_1_242_2","doi-asserted-by":"publisher","DOI":"10.1038\/282208a0"},{"key":"e_1_2_1_243_2","first-page":"R350","article-title":"Intravenous infusion of bombesin reduces food intake in humans","volume":"264","author":"Muurahainen NE","year":"1993","journal-title":"Am J Physiol"},{"key":"e_1_2_1_244_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1042\/cs0850277","article-title":"Bombesin reduces food intake after a preload in man by a cholecystokinin\u2010independent mechanism","volume":"85","author":"Lieverse RJ","year":"1993","journal-title":"Clin Sci"},{"key":"e_1_2_1_245_2","first-page":"579","article-title":"Significant satiety effect of bombesin in lean but not in obese subjects","volume":"18","author":"Lieverse RJ","year":"1994","journal-title":"Int J Obes"},{"key":"e_1_2_1_246_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(92)90106-Y"},{"key":"e_1_2_1_247_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(91)91644-G"},{"key":"e_1_2_1_248_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(91)90148-I"},{"key":"e_1_2_1_249_2","first-page":"R178","article-title":"Modulation of food intake by peripherally administered amylin","volume":"267","author":"Morley JE","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_1_250_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-15-2-163"},{"key":"e_1_2_1_251_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/cs0880007","article-title":"A reappraisal of current hypotheses concerning the possible roles of amylin in physiology, pathology and therapeutics","volume":"88","author":"Cooper GJS","year":"1995","journal-title":"Clin Sci"},{"key":"e_1_2_1_252_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400360"},{"key":"e_1_2_1_253_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)81113-M"},{"key":"e_1_2_1_254_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.40.8.948"},{"key":"e_1_2_1_255_2","doi-asserted-by":"publisher","DOI":"10.1006\/frne.1995.1013"},{"key":"e_1_2_1_256_2","doi-asserted-by":"publisher","DOI":"10.1038\/379069a0"},{"key":"e_1_2_1_257_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(93)90960-U"},{"key":"e_1_2_1_258_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00101-4"},{"key":"e_1_2_1_259_2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","article-title":"Long\u2010term pharmacotherapy in the management of obesity","volume":"276","author":"National Task Force on the Prevention and Treatment of Obesity","year":"1996","journal-title":"JAMA"},{"key":"e_1_2_1_260_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5301.751"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1997.tb04323.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1997.tb04323.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T23:39:16Z","timestamp":1745969956000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1997.tb04323.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":259,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1002\/j.1552-4604.1997.tb04323.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1997.tb04323.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}